Showing papers by "Horst Lindhofer published in 1999"
Patent•
22 Sep 1999
TL;DR: In this article, the time-staggered utilization of tumor cells in combination with intact, preferably heterologous antibodies for the immunization of humans and animals was proposed, which relates to the use of tumor stem cells for cancer immunization.
Abstract: The invention relates to the time-staggered utilization of tumor cells in combination with intact, preferably heterologous antibodies for the immunization of humans and animals.
50 citations
TL;DR: It is shown here that even pre‐existing tumours can be eradicated by trioma vaccination, that the trioma approach is superior to vaccination with cytokine gene‐modified autologous tumour cells and that there is a synergism between trioma immunisation and GM‐CSF gene transfer.
Abstract: The trioma approach is a new immunotherapeutic strategy for treating B-cell lymphomas. It is based on converting the tumour idiotype to a bispecific immunoglobulin that redirects the idiotype to antigen-presenting cells. We show here that even pre-existing tumours can be eradicated by trioma vaccination, that the trioma approach is superior to vaccination with cytokine gene-modified autologous tumour cells and that there is a synergism between trioma immunisation and GM-CSF gene transfer. Furthermore, we show that the immunising potential of GM-CSF gene-modified autologous lymphoma cells is not as dependent on the cytokine expression level as described for other tumour models, such that even minute expression rates are effective. IL-4 gene transfer in the lymphoma model is considerably less efficient or even ineffective when more sensitive systems are used. Remarkably, trioma-mediated effects are extinguished when IL-4 is expressed by the trioma cell.
17 citations
Patent•
05 Aug 1999
TL;DR: In this article, a human or animal cell expressing an antibody directed against a surface antigen on an antigen-presenting cell (APC) and lacking parental tumor-derived immunoglobulin was provided.
Abstract: According to the invention, there is provided a human or animal cell expressing an antibody directed against a surface antigen on an antigen-presenting cell (APC) and lacking parental tumor-derived immunoglobulin.
2 citations
Patent•
23 Jul 1999
Patent•
23 Jul 1999
TL;DR: In this paper, a human or animal tumor cell is provided that expresses an antibody that is directed against a surface antigen on an antigen-expressing cell (APC), and has the no test based on parental tumor immunoglobulin.
Abstract: According to the invention a human or animal tumor cell is provided that expresses an antibody that is directed against a surface antigen on an antigen-expressing cell (APC), and has the no test based on parental tumor immunoglobulin.